The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Comparison of phosphodiesterase type 5 (PDE5) inhibitors: COMPARISON OF PDE5 INHIBITORS
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another difference is that fatty food affects the pharmacokinetic profiles of sildenafil and vardenafil, but not that of tadalafil.22”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [22]
In the citing paper
“Compared with sildenafil and vardenafil, tadalafil is characterized by a long elimination half-life that allows for more flexibility of timing for patients.”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [22]
In the citing paper
“Sildenafil and vardenafil have similar molecular structures, but tadalafil differs in structure, which is reflected in its pharmacokinetic profile.”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [22]
In the citing paper
“Regarding its onset of action, i.e., achieving an erection that leads to successful intercourse, sildenafil and vardenafil both have half-lives of approximately 4 h, while the half-life of tadalafil is approximately 18 h.”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [22]
In the citing paper
“Sildenafil and vardenafil have similar molecular structures, but tadalafil differs in structure, which is reflected in its pharmacokinetic profile.”
From Treatment Strategy for Non-Responders to PDE5 Inhibitors (2013) · cites this paper as [22]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841 · cited 1×
“In a study of 110 men with ED and obesity, lifestyle changes have been shown to improve sexual function in approximately 30% of men.[ 10 ] Although the authors commented that contact with the”
Bacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00005 · Cited by 832 · cited 1×
“pharmacokinetics of the three currently available PDE5 inhibitors are not affected by alcohol, although men may wish to refrain from alcohol, as alcohol consumption has been shown to be associated with ED.[ 20 ]”
SHABSIGH, R., KAUFMAN, J. M., STEIDLE, C., & PADMA-NATHAN, H. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132389.97804.d7 · Cited by 406
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
Corbin, J., & Francis, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11296.x · Cited by 260
Research works printed but not linked: 49
- Aytac, 1999, The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences, BJU Int, 84, 50, 10.1046/j.1464-410x.1999.00142.x · DOI
- Mulcahy, 2000, Erectile dysfunction - is the incidence increasing, J Urol, 163, 471, 10.1016/S0022-5347(05)67903-7 · DOI
- Rosen, 1998, Sildenafil: medical advance or media event, Lancet, 351, 1599, 10.1016/S0140-6736(05)77682-0 · DOI
- Jardin, 2000, Erectile Dysfunction, 711
- Jackson, 2002, A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement - update 2002, Int J Clin Pract, 56, 663, 10.1111/j.1742-1241.2002.tb11349.x · DOI
- Meuleman, 2001, Erectile dysfunction: prevalence and effect on the quality of life; Boxmeer study, Ned Tijdschr Geneeskd, 145, 576
- Vitezic, 2002, Erectile dysfunction: oral pharmacotherapy options, Int J Clin Pharmacol Ther, 40, 393, 10.5414/CPP40393 · DOI
- Braun, 2000, Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’, Int J Impot Res, 12, 305, 10.1038/sj.ijir.3900622 · DOI
- Impotence Association Survey, 2002, Attitudes Towards Erectile Dysfunction
- Eardley, 2004, An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction, BJU Int, 93, 1271, 10.1111/j.1464-410X.2004.04816.x · DOI
- Saenz de Tejada, 2002, Comparative selectivity profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay, Int J Impot Res, 14, S25
- Nichols, 2002, Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality, Br J Clin Pharmacol, 53, 5S, 10.1046/j.0306-5251.2001.00027.x · DOI
- Stark, 2001, Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose, Eur Urol, 40, 181, 10.1159/000049770 · DOI
- Patterson, 2001, The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351), Int J Impot Res, 13, S62
- Porst, 2003, Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups, Urology, 62, 519, 10.1016/S0090-4295(03)00491-6 · DOI
- Rajagopalan, 2003, Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, J Clin Pharmacol, 43, 260, 10.1177/0091270002250604 · DOI · Paper page
- Boolell, 1996, Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res, 8, 47
- Padma-Nathan, 2003, Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial, Urology, 62, 400, 10.1016/S0090-4295(03)00567-3 · DOI
- Montorsi, 2004, Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial, J Sex Med, 1, 168, 10.1111/j.1743-6109.2004.04025.x · DOI
- Rosen, 2004, Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study, J Sex Med, 1, 193, 10.1111/j.1743-6109.2004.04028.x · DOI
- Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
- Hellstrom, 2002, Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, 763, 10.1002/j.1939-4640.2002.tb02332.x · DOI · Paper page
- Hellstrom, 2003, Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial, Urology, 61, 8, 10.1016/S0090-4295(03)00115-8 · DOI
- Stuckey, 2003, Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial, Diabetes Care, 26, 279, 10.2337/diacare.26.2.279 · DOI
- Carson, 2004, The efficacy and safety of tadalafil: an update, BJU Int, 93, 1276, 10.1111/j.1464-410X.2004.04819.x · DOI
- Padma-Nathan, 1998, Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group, Int J Clin Pract, 52, 375, 10.1111/j.1742-1241.1998.tb08886.x · DOI
- Olsson, 2001, Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease, Int J Clin Pract, 55, 171, 10.1111/j.1742-1241.2001.tb11009.x · DOI
- Padma-Nathan H Brock G McMahon C et al. Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension 2002 · DOI
- Kloner, 2004, Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men, J Urol, 172, 1935, 10.1097/01.ju.0000142687.75577.e4 · DOI
- Rendell, 1999, Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group, JAMA, 281, 421, 10.1001/jama.281.5.421 · DOI
- Goldstein, 2003, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study, Diabetes Care, 26, 777, 10.2337/diacare.26.3.777 · DOI
- Saenz de Tejada, 2002, Effects of tadalafil on erectile dysfunction in men with diabetes, Diabetes Care, 25, 2159, 10.2337/diacare.25.12.2159 · DOI · Paper page
- Montorsi, 2004, Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial, J Urol, 172, 1036, 10.1097/01.ju.0000136448.71773.2b · DOI · Paper page
- Montorsi, 2004, Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention, J Sex Med, 1, 322, 10.1111/j.1743-6109.04047.x · DOI
- Rosen, 2002, PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes, Annu Rev Sex Res, 13, 36, 10.1080/10532528.2002.10559802 · DOI
- Sommer, 2004, Future options for combination therapy in the management of erectile dysfunction in older men, Drugs Aging, 21, 555, 10.2165/00002512-200421090-00001 · DOI
- McCullough, 2002, Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction, Urology, 60, 28, 10.1016/S0090-4295(02)01688-6 · DOI
- McMahon, 2004, Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil, J Sex Med, 1, 292, 10.1111/j.1743-6109.04042.x · DOI · Paper page
- Morales, 2004, Endocrine aspects of sexual dysfunction in men, J Sex Med, 1, 69, 10.1111/j.1743-6109.2004.10111.x · DOI
- Hanson-Divers, 1998, Health outcomes variables important to patients in the treatment of erectile dysfunction, J Urol, 159, 1541, 10.1097/00005392-199805000-00037 · DOI
- Von Keitz, 2004, A multicenter, randomized, double-blind, crossover study to evaluate patient preference for tadalafil and sildenafil, Eur Urol, 45, 499, 10.1016/j.eururo.2003.11.030 · DOI · Paper page
- Stroberg, 2003, Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference, Clin Ther, 25, 2724, 10.1016/S0149-2918(03)80329-6 · DOI · Paper page
- Eardley, 2005, An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy, BJU Int, 96, 1323, 10.1111/j.1464-410X.2005.05892.x · DOI
- Mulhall, 2004, Understanding erectile dysfunction medication preference studies, Curr Opin Urol, 14, 367, 10.1097/00042307-200411000-00013 · DOI
- Mulhall, 2006, Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction, Eur Urol, 49, 30, 10.1016/j.eururo.2005.09.001 · DOI
- Ashton-Key, 2002, UK department of health guidance on prescribing for impotence following the introduction of sildenafil: potential to contain costs in the average health authority district, Pharmacoeconomics, 20, 839, 10.2165/00019053-200220120-00004 · DOI
- Loughney, 2005, 3′,5′-cyclic nucleotide phosphodiesterase 11A: localization in human tissues, Int J Impot Res, 17, 320, 10.1038/sj.ijir.3901317 · DOI
- Patterson, 2001, Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers, Int J Impot Res, 13, S63
- Riley, 2004, How does vardenafil hydrochloride (Levitra) treat erectile dysfunction, US Pharmacist
Cited by
Yuan, J., Zhang, R., Yang, Z., Lee, J., Liu, Y., Tian, J., Qin, X., Ren, Z., Ding, H., Chen, Q., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.012 · Cited by 260
Treatment Strategy for Non-Responders to PDE5 Inhibitors
Park, N. C., Kim, T. N., & Park, H. J. (2013) · The World Journal of Men's Health · doi:10.5534/wjmh.2013.31.1.31 · Cited by 41
Metadata
- Authors
- WRIGHT, P. J.
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2006-06-16
- Volume
- 60
- Issue
- 8
- Pages
- 967-975
- ISSN
- 1368-5031
- Cited by
- 138
- References
- 5
- Language
- en
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3364 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of phosphodiesterase type 5 (PDE5) inhibitors: COMPARISON OF PDE5 INHIBITORS. https://app.cochat.ai/papers/10.1111/j.1742-1241.2006.01049.x
- The paper
- WRIGHT, P. J. (2006). Comparison of phosphodiesterase type 5 (PDE5) inhibitors: COMPARISON OF PDE5 INHIBITORS. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2006.01049.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
